CEO , CG ONCOLOGY
WHY:Leads research for bladder cancer treatments that investors have called “game changers.”
IN THE NEWS:Raised oversubscribed $105M in August.
NOTABLE:Anti-cancer drugs for bladder treatments often ineffective because urinated; CG instead uses genetically modified viruses to target tumors.
QUOTABLE:“We are encouraged to see our treatments get closer to being available to bladder cancer patients worldwide.”
